FDA Assigns Facility Inspection for OLC, Unicycive Plans NDA Resubmission
UNCY sits 37% above its 52-week low of $3.71 on light trading volume (0.3× avg).
Summary
Unicycive's Q2 update brings a concrete regulatory step: the FDA has assigned a facility inspection to the third-party manufacturer of OLC, the key hurdle from the June CRL. The company expects to resubmit the NDA upon a successful inspection, keeping the drug on track for potential approval. Financially, the net loss narrowed to $1.7M from $6.5M a year ago, aided by a non-cash warrant liability gain, while cash of $61.4M provides runway into 2027. This follows the June CRL and the recent 10-Q filing, but the inspection assignment is new and moves the timeline forward. The next catalyst is the inspection outcome, which will determine the resubmission timing.
At the time of this announcement, UNCY was trading at $5.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.5M. The 52-week trading range was $3.71 to $8.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.